Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trial Management

Background:

• Industry interest in anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy for B-cell malignancies has surged due to recent clinical trial successes.
• There is a growing need to rapidly and safely integrate industry-sponsored pivotal trials into clinical practice.
• Preparing for diverse cell therapies, including those for solid tumors, requires specialized infrastructure and coordination.

Purpose of the Study:

• To establish a collaborative, cross-departmental program for the clinical care and trial coordination of immune cell therapies.
• To centralize the administration of CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T-cell receptor (TCR) therapy.
• To leverage existing expertise and infrastructure from a Blood and Marrow Transplantation program to support novel cell therapies.

Main Methods:

• Implementation of a collaborative, cross-departmental program named Moffitt Immune Cell Therapy (ICE-T).
• Centralization of clinical care and trial coordination for immune cell therapies.
• Leveraging the infrastructure of an established Blood and Marrow Transplantation program.

Main Results:

• The ICE-T program successfully centralizes the administration of CAR T-cell therapy for hematologic malignancies.
• The program also oversees and administers TIL and TCR therapies for solid tumor patients.
• Disease-specific experts maintain oversight as principal investigators, ensuring specialized care.

Conclusions:

• A centralized, collaborative program can effectively facilitate the integration of industry-sponsored and investigator-initiated cell therapy trials.
• The ICE-T program provides a robust framework for delivering advanced immune cell therapies, including CAR T-cell, TIL, and TCR therapies.
• This model enhances patient access to cutting-edge cancer treatments by optimizing clinical care and trial coordination.